In fact, endocan was already shown to lose its prognostic ability after dexamethasone administration [29] and, apparently, the association between survival and the reduction of endocan concentration occurred only in COVID-19 on VV-ECMO patients not treated with dexamethasone [40]. The gene discussed is ESM1; the disease is COVID-19.